Related Experiment Video
Updated: Mar 30, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Hyponatraemia induced by terlipressin: a case report and literature review
1Department of Infectious Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
What Is Known And Objective:
Terlipressin is widely used to treat variceal bleeding and hepatorenal syndrome. We report one case of stubborn hyponatraemia induced by long-term (up to 21 days) therapy with terlipressin and review the side effects of this agent.
Case Summary:
A 41-year-old man with variceal rebleeding experienced a course of stubborn hyponatraemia during a long-term (up to 21 days) therapy with terlipressin. The hyponatraemia could not be corrected until withdrawal of terlipressin. The adverse event is likely due to the stimulation of V1 receptors in the splanchnic area and V2 receptors in the collecting duct.
What Is New And Conclusion:
Given that this reaction has rarely been reported, we discuss the present case with a review of other similar cases. Serum sodium should be monitored intensively to avoid misdiagnosis whenever terlipressin treatment is employed for either gastrointestinal haemorrhage or hepatorenal syndrome.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Acute Kidney Injury VI: Nursing Management
Antihypertensive Drugs: Action of Diuretics
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Acute Kidney Injury V: Interprofessional Care

